Sildenafil for Male Erectile Dysfunction

Fink, Howard A; Donald, Roderick Mac; Rutks, Indulis; Nelson, David B.; Wilt, Timothy J

doi:10.1001/archinte.162.12.1349

Cited by 221 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite clinical trials data illustrating a high level of efficacy (successful sexual intercourse attempt rates for sildenafil were 83% vs 45% with a placebo [4]) and a discontinuation rate as low as 7% [4], PDE5i usage suffers a significant dropout rate of about 50% [5]. This observation is not explained by the natural course of the disease.…”

Section: Introductionmentioning

confidence: 94%

Salvaging the oral treatment failure patient

Pescatori

Drei²,

Morgia³

et al. 2006

Curr sex health rep

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 94%

Salvaging the oral treatment failure patient

Pescatori

Drei²,

Morgia³

et al. 2006

Curr sex health rep

View full text Add to dashboard Cite

“…6,7 Reasons for this include a lack of training of health care professionals, discomfort of providers with the topic, and insufficient time during visits for discussion. 1 However, effective strategies for treating both female and male sexual dysfunction exist, 8–11 making these discussions a critical part of survivorship care.…”

Section: Overviewmentioning

confidence: 99%

“…8,10 Many studies have also shown the efficacy and tolerability of PDE5i for treating ED in patients with cancer and survivors. 24,25 Importantly, PDE5is are contraindicated in patients taking oral nitrates, because together they can lead to a dangerous decrease in blood pressure.…”

Section: Interventions For Male Sexual Dysfunctionmentioning

confidence: 99%

Survivorship: Sexual Dysfunction (Male), Version 1.2013

Denlinger¹,

Carlson²,

Are³

et al. 2014

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Various anticancer treatments, especially those directed toward the pelvis, can damage blood vessels and reduce circulation of blood to the penis and/or damage the autonomic nervous system, resulting in higher rates of erectile dysfunction in survivors than in the general population. In addition, hormonal therapy can contribute to sexual problems, as can depression and anxiety, which are common in cancer survivors. This section of the NCCN Guidelines for Survivorship provides screening, evaluation, and treatment recommendations for male sexual problems, namely erectile dysfunction.

show abstract

“…This approach yielded several classic drugs. One is sildenafil, which was originally discovered as a treatment for various cardiovascular disorders in 1989 and now is sold with the brand name Viagra to treat erectile dysfunction (Fink et al, 2002). Another is azidothymidine, which originally failed as a chemotherapy anticancer drug due to the lack of efficacy but emerged in the 1980s as a therapy for HIV (D'Andrea et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Zhang

Musharrafieh

et al. 2017

Antiviral Research

View full text Add to dashboard Cite

The emergence of multidrug-resistant influenza viruses poses a persistent threat to public health. The current prophylaxis and therapeutic interventions for influenza virus infection have limited efficacy due to the continuous antigenic drift and antigenic shift of influenza viruses. As part of our ongoing effort to develop the next generation of influenza antivirals with broad-spectrum antiviral activity and a high genetic barrier to drug resistance, in this study we report the discovery of dapivirine, an FDA-approved HIV nonnucleoside reverse transcriptase inhibitor, as a broad-spectrum antiviral against multiple strains of influenza A and B viruses with low micromolar efficacy. Mechanistic studies revealed that dapivirine inhibits the nuclear entry of viral ribonucleoproteins at the early stage of viral replication. As a result, viral RNA and protein synthesis were inhibited. Furthermore, dapivirine has a high in vitro genetic barrier to drug resistance, and its antiviral activity is synergistic with oseltamivir carboxylate. In summary, the in vitro antiviral results of dapivirine suggest it is a promising candidate for the development of the next generation of dual influenza and HIV antivirals.

show abstract

Sildenafil for Male Erectile Dysfunction

Abstract: Sildenafil improves erectile function and is generally well tolerated. Treatment response seems to vary between patient subgroups, although sildenafil has greater efficacy than placebo in all evaluated subgroups.

Cited by 221 publications

References 31 publications

Salvaging the oral treatment failure patient

Salvaging the oral treatment failure patient

Survivorship: Sexual Dysfunction (Male), Version 1.2013

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Contact Info

Product

Resources

About